2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Coagulopathy: new trials by email Literature Review of Coagulopathy trials Research Report on Coagulopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Camostat Mesylate, Microcrystalline Cellulose, NF - Coagulopathy, Cardiovascular Complication | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-11-01 | 2022-05-18 | |
| The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Aspirin 81 mg, Vitamin D - COVID, Vitamin D Deficiency | Phase 2 | Withdrawn | Louisiana State University Health Sciences Center in New Orleans | 2020-05-01 | 2021-12-27 |
Hemostatic Disorders (2) · COVID-19 (1) · Disseminated Intravascular Coagulation (1) · Vitamin D Deficiency (1)
Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Vascular Diseases (2) · Avitaminosis (1) · Blood Coagulation Disorders (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Deficiency Diseases (1) · Infections (1) · Lung Diseases (1) · Malnutrition (1) · Nidovirales Infections (1) · Nutrition Disorders (1)
Aspirin (1) · Vitamin D (1) · camostat (1) · microcrystalline cellulose (1)
Louisiana State University Health Sciences Center in New Orleans (1) · Yale University (1)
Arya Mani, MD (1) · Frank H Lau, MD (1)